ArticleCancer discovery2014

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Justin M Balko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.